Answers are grounded in this paper and cite their sources.
Pulmonary hypertension is a severe cardiovascular disease followed by extremely poor prognosis without treatment. To date, prostanoids in all their forms are effective for pulmonary hypertension, but their use is significantly limited due to peculiarities of delivery of active molecules and side effects caused by unique characteristics of biochemical reactions. This review highlights the possibilities and limitations of these drugs, in particular inhaled iloprost. It is the only drug approved for pulmonary hypertension in our country. We also discuss the prospects for further use of prostanoids and overcoming existing limitations.
No takes yet. Share an insight, caveat, or question.
Tkacheva et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: